Expertise in
2
conditions

Guillem Argiles

Barcelona, CT, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Barcelona, CT, ES 

Overview

Guillem Argiles practices practicing medicine in Barcelona, Spain.

Argiles is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Colorectal Cancer, PIK3CA-Related Overgrowth Spectrum, Agranulocytosis, and Diarrhea.

They are actively involved in clinical research, co-authoring 85 peer reviewed articles and participating in 2 clinical trials.

Locations

Barcelona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Combination product, Drug
Study Drug: MCLA-158
Study Phase: Phase 1/Phase 2
A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine to Determine Safety and Preliminary Efficacy of the Combination in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients.
A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine to Determine Safety and Preliminary Efficacy of the Combination in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients.
Enrollment Status: Completed
Publish Date: October 06, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

84 Total Publications

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.
Journal: ESMO open
Published: October 28, 2025

Frequently Asked Questions about Guillem Argiles

Is Guillem Argiles a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Guillem Argiles is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Guillem Argiles participate in research or clinical trials?

Yes. Guillem Argiles has published 84 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Guillem Argiles's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Argiles's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile